Perspective Therapeutics, Inc. · AMEX:CATX

Perspective Therapeutics — Investor Presentation (January 2026)

33 slides from Perspective Therapeutics's investor presentation, Jan 14, 2026

  1. Slide 1: Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

    Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s

  3. Slide 3: Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology

    Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology

  4. Slide 4: Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

    Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

  5. Slide 5: Proprietary Radioligand Platform Optimizes Therapeutic Index

    Proprietary Radioligand Platform Optimizes Therapeutic Index

  6. Slide 6: Proprietary Pb-Based Chelator Designed for Broader and Safer Use

    Proprietary Pb-Based Chelator Designed for Broader and Safer Use

  7. Slide 7: Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters

    Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters

  8. Slide 8: Imaging Optimizes Targeted Delivery to Tumor

    Imaging Optimizes Targeted Delivery to Tumor

  9. Slide 9: Compoun

    Compoun AVAV AN & Br Baw dgoorrenen 2 * Phage display followed by affinity maturation * Bioconjugate chemistry and further optimization * In vitro and in vivo binding assays identified lead candidates?

  10. Slide 10: Solid Tumors are an Attractive Market for Radiopharmaceuticals

    Solid Tumors are an Attractive Market for Radiopharmaceuticals

  11. Slide 11: End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway

    End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway

  12. Slide 12: Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

    Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

  13. Slide 13: SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

    SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

  14. Slide 14: VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

    VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

  15. Slide 15: Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

    Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

  16. Slide 16: Compelling Anti-tumor Activity with Sustained or Deepening Responses

    Compelling Anti-tumor Activity with Sustained or Deepening Responses

  17. Slide 17: Best-in-class Safety Profile

    Best-in-class Safety Profile1

  18. Slide 18: VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

    VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

  19. Slide 19: Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

    Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

  20. Slide 20: VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

    VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

  21. Slide 21: Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

    Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

  22. Slide 22: Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

    Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

  23. Slide 23: Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

    Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

  24. Slide 24: VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

    VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

  25. Slide 25: FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

    FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

  26. Slide 26: PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

    PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

  27. Slide 27: Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

    Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

  28. Slide 28: PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

    PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

  29. Slide 29: Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

    Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

  30. Slide 30: Strong Financial Position

    Strong Financial Position Funding into late 2026 Cash, cash equivalents and short-term investments as of September 30, 2025 ~$174.1 million Share count as of September 30, 2025 ~74.3 million Outstanding common stock warrants & options as of September 30, 2025 ~10.9 million Based on our current plans

  31. Slide 31: Phase 1/2 Data Expected Across All Clinical Programs in 26

    Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026

  32. Slide 32: Slide 32

  33. Slide 33: Abbreviations

    Abbreviations AE: adverse event ALP: alkaline phosphatase ALT: alanine transaminase ASCO: American Society of Clinical Oncology ASCO-GI: ASCO Gastrointestinal Cancers Symposium AST: aspartate aminotransferase AUC: area under the curve CR: complete response CT: computed tomography Cmax: peak concentr

Perspective Therapeutics — Investor Presentation (January 2026) on 6ix